Due to earlier findings (see above) suggesting a neuroprotective effect of Cav1.3 inhibition in early PD (see Liss & Striessnig, 2019; Surmeier, Halliday, & Simuni, 2017, for reviews) the authors tested whether this compound has neuroprotective properties in a mouse 6‐hydroxydopamine (6‐OHDA) PD model. The gene discussed is CACNA1D; the disease is Parkinson disease.